Share This

Related Topics News -

     
 Title only   |   Print    Next page > 
     
和鉑醫藥-B主席自願承諾禁售持股份至少六個月

2024-04-17T  
《公司業績》和鉑醫藥全年純利2,280萬美元 虧轉盈

2024-03-31T  
和鉑醫藥-B夥Boostimmune合作開發抗體偶聯藥物療法

2024-02-27T  
和鉑醫藥-B旗下雙特異性抗體HBM9027獲美國新藥研究申請許可

2024-01-24T  
和鉑醫藥-B抽升逾7% 料去年虧轉盈

2024-01-19T  
《盈利預喜》和鉑醫藥-B料2023財年轉盈 賺1,800萬美元

2024-01-19T  
和鉑醫藥-B與Seagen就HBM9033全球臨床開發及商業化簽訂許可協議

2023-12-15T  
和鉑醫藥預期明年上半年重新提交巴托利單抗BLA

2023-12-03T  
和鉑醫藥-B獲美國FDA新藥研究申請許可

2023-08-28T  
《公司業績》和鉑醫藥-B半年虧轉盈賺292.2萬美元

2023-08-28T  
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.